Full text
Earnings transcript
Read the complete earnings call transcript.
MYGN
Myriad Genetics, Inc.
$4.54
0.15
(3.42%)
| Exchange: | NASDAQ |
| Market Cap: | 428.795M |
| Shares Outstanding: | 30.256M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Samraat S. Raha | |||||
| Full Time Employees: | 2700 | |||||
| Address: |
| |||||
| Website: | https://myriad.com |
Myriad Genetics, Inc. is a leading company specializing in genetic testing and precision medicine. The firm focuses on developing and marketing a wide array of genetic diagnostic solutions across both domestic U.S. and international landscapes. Their extensive diagnostic offerings cater to crucial medical fields, including oncology, women’s health, and mental well-being. In cancer diagnostics, Myriad provides several sophisticated molecular tests. These include the MyRisk Hereditary Cancer Test, which uses DNA sequencing to evaluate an individual’s susceptibility to inherited cancer types. The BRACAnalysis CDx functions as a vital companion diagnostic, leveraging DNA sequencing to inform treatment strategies for patients with metastatic breast, ovarian, pancreatic, or prostate cancers carrying specific deleterious BRCA gene variants. Another key oncology product, the MyChoice CDx, is a tumor-based assay designed to ascertain homologous recombination deficiency status in ovarian cancer patients. Myriad also offers prognostic tools like the Prolaris Prostate Cancer Prognostic Test and the EndoPredict Breast Cancer Prognostic Test, both employing RNA expression analysis to gauge the aggressiveness of prostate and breast cancers, respectively. Furthermore, they offer Precise Tumor, a comprehensive solution aimed at guiding personalized cancer treatment. For women’s health and prenatal care, Myriad presents essential screening options. The Prequel Prenatal Screen is a non-invasive maternal blood test used to identify significant chromosomal abnormalities in a fetus. Prospective parents can also utilize the Foresight Carrier Screen to assess their risk of transmitting recessive genetic conditions to their children. Addressing mental health, Myriad offers the GeneSight Psychotropic Mental Health Medication Test. This DNA genotyping test assists healthcare providers in optimizing the selection of psychotropic medications for individuals suffering from conditions such as depression, anxiety, and ADHD. Myriad Genetics has also established strategic alliances, notably with Illumina, Inc. and Intermountain Precision Genomics, to enhance its provision of both germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 753,200 | 837,600 | 824,500 |
| Gross Profit | 517,000 | 585,400 | 576,600 |
| EBITDA | -197,400 | -59,500 | -330,900 |
| Operating Income | -257,400 | -123,500 | -67,800 |
| Net Income | -263,300 | -127,300 | -365,900 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,146,500 | 1,027,600 | 706,600 |
| Total Liabilities | 363,300 | 326,500 | 338,600 |
| Total Stockholders Equity | 783,200 | 701,100 | 368,000 |
| Total Debt | 152,100 | 140,300 | 209,800 |
| Cash and Cash Equivalents | 132,100 | 102,400 | 149,600 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -110,900 | -8,700 | 1,800 |
| Capital Expenditure | -73,300 | -29,700 | 0 |
| Free Cash Flow | -184,200 | -38,400 | 1,800 |
| Net Income | -263,300 | -127,300 | 0 |
| Net Change in Cash | 74,500 | -29,000 | 39,400 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,088,034.543 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 1,106,730.310 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 1,096,100 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -186,261.430 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -183,114.954 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -184,472.361 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 59,141.004 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 60,464.931 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 59,712 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 787,447.553 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 800,978.315 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 793,284.799 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 0.640 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 0.650 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 0.630 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 3 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about MYGN valuation
Is Myriad Genetics, Inc. (MYGN) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Myriad Genetics, Inc. (MYGN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is MYGN a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MYGN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is MYGN’s P/E ratio?
You can see MYGN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for MYGN?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is MYGN a good long-term investment?
Whether MYGN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
MYGN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
3.42
Trading Metrics:
| Open: | 4.42 | Previous Close: | 4.39 | |
| Day Low: | 4.32 | Day High: | 4.54 | |
| Year Low: | 3.53 | Year High: | 8.59 | |
| Price Avg 50: | 4.44 | Price Avg 200: | 5.93 | |
| Volume: | 1.138M | Average Volume: | 1.924M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
